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ACSL – very long-chain acyl-CoA synthetase 
ALA – -linolenic acid 
ARA – arachidonic acid 
DHA – docosahexaenoic acid 
DGLA – dihomo--linolenic acid 
DPAn-3 – n-3 docosapentaenoic acid 
DPAn-6 – n-6 docosapentaenoic acid 
ELOVL – elongation of very long-chain 
EPA – eicosapentaenoic acid 
FADS – fatty acid desaturase 
FPUFA – turnover 
GC-MS – gas chromatography-mass spectrometry 
GLA – -linolenic acid 
k1,PUFA – synthesis-secretion coefficient 
LNA – linoleic acid 
PC – phoshatidylcholine 
PE – phosphatidylethanolamine 
PFB – pentafluorylbenzyl 
PS – phosphatidylserine 
PUFA – polyunsaturated fatty acid 
SDA – stearidonic acid  
Smax – maximum first derivative 
t1/2,PUFA – half-life 
TAG – triacylglycerol 
THA – tetracosahexaenoic acid 
TLE – total lipid extract 
TPAn-3 – n-3 tetracosapentaenoic acid 













 Docosahexaenoic acid (DHA, 22:6n-3) must be consumed in the diet or synthesized from n-3 
polyunsaturated fatty acid (PUFA) precursors.  However, the effect of dietary DHA on the metabolic 
pathway is not fully understood.  Presently, 21-day old Long Evans rats were weaned onto one of four 
dietary protocols: 1) 8 weeks of 2% ALA (ALA), 2) 6 weeks ALA followed by 2 weeks of 2% ALA + 





C20-eicosapentaenoic acid (EPA, 20:5n-3) were co-infused and blood was 
collected over three hours for determination of whole-body synthesis-secretion kinetics.  The synthesis-
secretion coefficient (ml/min, means ± SEM) for EPA (0.238 ± 0.104 vs. 0.021 ± 0.001) and DPAn-3 
(0.194 ± 0.060 vs. 0.020 ± 0.008) synthesis from plasma unesterified ALA, and DPAn-3 from plasma 
unesterified EPA (2.04 ± 0.89 vs. 0.163 ± 0.025) were higher (p < 0.05) after 2 weeks compared to 8 
weeks of DHA feeding. The daily synthesis-secretion rate (nmol/d) of DHA from EPA was highest after 4 
weeks of DHA feeding (843 ± 409) compared to no DH  (70 ± 22).  Liver gene expression of ELOVL2 
and FADS2 were lower (p < 0.05) after 4 versus 8 weeks of DHA.  Higher synthesis-secretion kinetics 
after 2 and 4 weeks of DHA feeding suggests an increased throughput of the PUFA metabolic pathway.  
Furthermore, these findings may lead to novel dietary strategies to maximize DHA levels while 
minimizing dietary requirements.   
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1.     Introduction 
 N-3 polyunsaturated fatty acids (PUFA) such as docosahexaenoic acid (DHA, 22:6n-3) that are 
high in the heart [1] and brain [2, 3] must be synthesized from shorter chain n-3 PUFA or consumed 
directly from the diet.  Specifically, -linolenic acid (ALA, 18:3n-3) is the most consumed n-3 PUFA in 
the North American diet consumed primarily from cooking oil sources such as vegetable seed oils and 
soybean oils [4].  DHA synthesis rates from ALA are considered to be very low [5-15], however these 
studies did not consider the synthesis of DHA from alternative metabolic precursors such as 
eicosapentaenoic acid (EPA, 20:5n-3).  When co-infusing ALA and EPA tracers simultaneously in 
rodents, our lab has demonstrated that the daily synthesis-secretion rate of DHA from plasma unesterified 
EPA (172 ± 62 nmol/d) is not statistically different than from ALA (98 ± 28 nmol/d [16].  This results in 
a total DHA synthesis-secretion rate of 270 nmol/d – nearly 3 times that of ALA alone – and suggests that 
DHA synthesis rates have been underestimated and may not be as low as previously determined.  
Furthermore, DHA synthesis rates from plasma unesterified ALA appear to be more than sufficient to 
meet brain DHA requirements [17], however, synthesis rates in relation to whole-body DHA 
requirements have not been assessed.  
 The effect of a wide range of dietary linoleic acid (LNA, 18:2n-6) [18] and ALA [19] 
compositions over 8 weeks have been determined on DHA synthesis-secretion kinetics.  Briefly, 
increasing dietary ALA from 3% to 10% of total fat in rodents does not affect daily DHA synthesis-
secretion rates despite a higher capacity for DHA synthesis following the 3% ALA diet [19].  Increasing 
dietary linoleic acid (LNA, 18:2n-6) from 10% to 40% of total fat in the diet of rodents does not increase 
synthesis-secretion rates of DHA, nor is there an effect on capacity for DHA synthesis-secretion [18].  
However, in both studies increasing dietary ALA and LNA from 0.1% and 1.5%, respectively, increases 
daily synthesis-secretion rates and capacity for synthesis-secretion.  Although DHA synthesis kinetics 
appear to be alterable across a range of ALA consumption, human interventions suggest that ALA intakes 












 Dietary consumption of DHA itself is the most efficient way to increase plasma DHA levels [20], 
and it is commonly believed that DHA intake will decrease or even shut down DHA synthesis from 
metabolic precursors.  Humans fed 6.5 grams per day of DHA for 90 days demonstrate significantly lower 
deuterated n-3 metabolites in plasma, including DHA, compared to a low DHA diet following an oral 
dose of deuterated ALA [8].  Conversely, EPA + DHA intake of 1.5 grams per day did not alter the 
conversion of labeled ALA into plasma DHA, but did show increases in labeled plasma 
phosphatidylcholine (PC) EPA and n-3 docosapentaenoic acid (DPAn-3, 22:5n-3) [5].  Additionally, 
studies in rats have shown an inhibition of DHA and/or n-3 synthesis in response to increases in dietary 
DHA [21, 22].  However, the aforementioned human and rodent studies utilize oral tracers to determine 
the appearance of labeled n-3 PUFA over hours and days, and are thus unable to account for turnover of 
synthesized DHA, such as that which is metabolized for other functions in body.  Using a 3-hour infusion 
model our lab has attempted to ameliorate these limitations and has demonstrated that dietary DHA (2% 
of total fat) over 15 weeks shuts down DHA synthesis from ALA [17].  However, the diet also contained 
very low amounts of dietary ALA (0.25% of total fat), thus potentially limiting substrate availability for 
DHA synthesis.  In the presence of sufficient ALA, the effect of acute dietary DHA consumption on DHA 
synthesis may be different and has not been previously assessed. Therefore, an assessment of the effect of 
DHA feeding over time in the presence of similar amounts of dietary ALA is warranted.  
 In the present study, we aimed to determine the effects of short- and long-term DHA intake on the 
synthesis-secretion kinetics of n-3 PUFA.  To address this, rats were weaned onto one of four diets for a 
total of 8 weeks providing 0, 2, 4 or 8 weeks of 2% DHA in total fatty acids.  Synthesis-secretion kinetics 




C20-EPA over 3 hours in unrestrained free-
living rats.  Briefly, we determined that 2 weeks of dietary DHA significantly increased the synthesis-
secretion coefficient for EPA and DPAn-3 from plasma unesterified ALA, and for DPAn-3 from plasma 
unesterified EPA.  The daily-synthesis-secretion rate was also higher after 4 weeks of DHA compared to 
the ALA control diet.  Higher synthesis-secretion kinetics after 2 and 4 weeks of dietary DHA suggests an 












levels more rapidly.  Furthermore, these findings may lead to the implementation of new dietary strategies 













2.    Materials and Methods 
2.1  Animals 
All experimental procedures were performed in agreement with the policies set out by the 
Canadian Council on Animal Care and were approved by the Animal Ethics Committee at the University 
of Toronto.  Four Long Evans dams with eight 18-day-old male non-littermate Long Evans pups were 
ordered from Charles River Laboratories (St. Constant, QC, Canada).  Following arrival at the University 
of Toronto, the dam and pups were acclimated for 3 days on the 2% ALA diet and then weaned at 21 days 
old.  At weaning, the 21-day-old pups were placed on a 10% by weight fat diet containing either 2% ALA 
(% weight) in total fatty acids or 2% DHA + 2% ALA in total fatty acids as the only dietary n-3 fatty 
acids following one of four dietary protocols: 1) 8 weeks of 2% ALA (0DHA), 2) 6 weeks of 2% ALA 
then 2 weeks of 2% DHA + 2% ALA (2DHA), 3) 4 weeks of 2% ALA then 4 weeks of 2% DHA + 2% 
ALA (4DHA) or 4) 8 weeks of 2% DHA + 2% ALA (8DHA) (Figure 1).  Each dietary protocol lasted 
eight weeks following weaning until 11 weeks of age.  During this time and prior to cannulation, rats 
were handled frequently and housed in pairs [16].   
 
2.2  Diets 
The diets were modified from the AIN-93G custom low n-3 PUFA rodent diet (Dyets, Inc., 
Bethlehem, PA) [23, 24].  The diets contained 10% lipids by weight, and the fat content of the diet by 
weight was 32.8% safflower oil, 63.2% hydrogenated coconut oil and 4% added fatty acid ethyl esters.  
The added ethyl esters were 2% oleate ethyl ester (Nu-Chek Prep, Inc., Elysian, MN) and 2% ALA ethyl 
ester (gift from BASF Pharma Callanish Ltd., Isle of Lewis, UK) for the 2% ALA diet, and 2% DHA 
ethyl ester (gift from BASF Pharma Callanish Ltd.) and 2% ALA ethyl ester for the 2% DHA + 2% ALA 
diet. Added ethyl ester oils were the only n-3 fatty acids present in the diet.  Each oil was determined to 
be >98% pure by GC-FID.  Actual composition of the diets was determined at the time of use by GC-FID 
to be 2.07 ± 0.01 % (mean ± SEM) by weight ALA in total fatty acids in the ALA diet, and 1.72% DHA 



















At 8 weeks post-weaning, 11-week-old rats were subjected to surgery to implant a catheter into 
each of the jugular vein and the carotid artery, as previously described in detail [18].  Baseline plasma 
unesterified and total fatty acid concentrations were measured in plasma drawn from the carotid artery 
one day after surgery and two days prior to stable isotope infusion.  Modified from the method of 
Rapoport, Igarashi, and Gao [25] and Domenichiello et al. [17], animals were co-infused with 0.563 
mol/100 g body weight of 
2
H5-ALA (purity >95% confirmed by GC-FID and GC-mass 
spectrometry(MS); Cambridge Isotope Laboratories, Inc., Tewksbury, MA), 0.281 mol/100 g body 
weight of 
13
C20-EPA (generously provided by Dr. Joseph Hibbeln, National Institutes of Health) and 2.25 
mol/100 g body weight of 
13
C18-LNA (Cambridge Isotopes) into the jugular vein for 180 min.  Infusate 
preparation, 3-hour steady-state infusions and blood collections from the carotid artery (0, 30, 60, 90, 120, 
150 and 180 min) were performed as previously described in detail [18].  All blood samples were 
centrifuged for 15 min at 500g (PC-100 microcentrifuge; Diamed, ON, Canada) and the plasma was 
collected and stored at -80°C.  Total blood plasma volumes were determined using the method of 
Schreihofer, Hair and Stepp and modified by our lab [17, 26]. 
 
2.4  Lipid Extractions from Baseline Serum 
 Total lipid extracts (TLE) for total fatty acid and for unesterified fatty acid measurements were 
obtained from 10L and 40L of serum, respectively, by a method modified from Folch, Lees, and 
Sloane Stanley [27] and described in detail previously [28].  Briefly, lipids were extracted with 2:1:0.75 
chloroform:methanol:0.88% potassium chloride (v:v:v) a known amount of heptadecanoic acid (17:0, 
NuChek Prep Inc., Elysian, MN, USA) as internal standard.  The mixtures were vortexed, centrifuged at 
500 g for 10 min, and the lower, chloroform lipid-containing layer was pipetted into a new test tube.  
TLEs for total fatty acid determinations were stored for hydrolysis as described later.  TLEs for 












fatty acids were collected, isolated from silica gel and stored for derivatization to pentafluorylbenzyl 
(PFB) esters as described in detail previously [28, 29].   
 
2.5  Lipid Extractions from Stable Isotope Infused Plasma 
TLE were obtained from 50 L of stable isotope infused plasma by the Folch method as 
described earlier containing a known amount of heptadecanoic acid (NuChek Prep Inc.) as internal 
standard.  Four-fifths of the TLE was stored for hydrolysis and stable isotope enrichment of total fatty 
acids, and the remaining one-fifth of the TLE was used for isolation of isotopically labeled unesterified 
fatty acid by the TLC method described earlier.  The isolated labeled unesterified fatty acids were stored 
for later derivatization to PFB esters.   
 
2.6  Hydrolysis of Total Endogenous and Isotopically Labeled Total Fatty Acid Pools 
 The TLE from baseline serum and infused plasma used to determine endogenous and labeled 
fatty acid concentrations, respectively, was evaporated under nitrogen and the lipids were hydrolyzed in 2 
mL of 10% potassium hydroxide in methanol (w:v), as previously described [16, 29, 30]. Hydrolyzed 
fatty acids from the total lipid pool were collected and stored at -80 °C for later derivatization to PFB 
esters. 
 
2.7  PFB Esterification 
 The plasma unesterified fatty acids and hydrolyzed fatty acids from total lipid pools were dried 
under nitrogen and derivatized to PFB esters, as previously described [29].  Briefly, 100 L of 
acetonitrile:diisoproplyamine:pentafluorylbenzyl bromide (1000:10:1, v:v:v) was added and heated at 60 
°C for 15 minutes.  The reagents were then evaporated under nitrogen, re-aliquoted in 40 L of hexane 













2.8  Endogenous and Labeled Fatty Acid Determination by GC-MS 
Fatty acid PFB esters were analyzed on an Agilent 5977A quadrupole mass spectrometer coupled 
to an Agilent 7890B gas chromatograph (Agilent Technologies, Mississauga, ON) in negative chemical 
ionization mode, as described previously [29] and recently modified by our lab [30].  The fatty acid PFB 
esters were injected via an Agilent 7693 autosampler into a DB-FFAP 30 m x 0.25 mm i.d. x 25 m film 
thickness capillary column (J&W Scientific from Agilent Technologies, Mississauga, ON) interfaced 
directly into the ion source with helium as the carrier gas.  Fatty acids were analyzed in selected ion 
monitoring mode using [M-H]- for parent ion identification with ion dwell times of 500 s. The [M-H]- 
parent ions for endogenous and labeled fatty acids are presented in Supplemental Table 1.  
 
2.9  Whole Blood Complex Acyl-Lipid Species Determination by UPLC-MS/MS 
 Baseline whole blood samples were collected one day post-surgery and two days prior to 
infusions and frozen at -80°C for later analysis of complex acyl-lipid species [31].  Total lipids were 
extracted by a modified Folch method from 50 L of whole blood by the method described earlier 
containing a mix of deuterated internal standards (Splash Lipidomix, Avanti Polar Lipids, Alabaster, AL, 
USA). Lipid extracts were dried under a stream of N2 gas and reconstituted in 100 L 65:35:5 
isopropanol:acetonitrile:water + 0.1% formic acid, and were stored at 4ºC until analysis by a Waters 
ACQUITY UPLCI-Class system coupled to a Waters Synapt G2Si Quadrupole-Time-of-Flight mass 
spectrometer (Waters Inc., Milford, MA, USA). A reversed phase, binary multi-step ultra-high 
performance liquid chromatography (UHPLC) protocol was used with a Waters ACQUITY CSH C18 
column, with dimensions 15 cm x 2.1 mm x 1.7 μm. The mobile phase consisted of A: 60:40 
acetonitrile:water + 10mM ammonium formate + 0.1% formic acid, and B: 90:10 isopropanol:acetonitrile 
+ 10mM ammonium formate + 0.1% formic acid. The gradient protocol used was as follows: 32% B from 
0 – 1.5 min, 45% B from 1.5 – 4 min, 50% B from 4 – 8 min, 55% B from 8 – 18 min, 60% B from 18 – 












B from 45 – 47 min, and allowed to equilibrate until the 48 minute mark. The flow was set at 260 μL/min, 
column temperature at 45°C and tray temperature at 4°C.  The mass spectrometer was operated in High 
Resolution negative ion mode, scan range 100 to 1200 m/z, and tandem mass spectrometry data was 
acquired under data-independent acquisition conditions. Compound identifications and extracted ion peak 
areas were generated using MassLynx Software (Waters Inc., Milford, MA, USA).  Raw peak areas were 
normalized within complex lipid classes using the appropriate internal standards from the Splash 
Lipidomix mix, such that all native phosphatidylcholine (PC) species were normalized using the PC 
internal standard peak, phosphatidylethanolamine (PE) species were normalized using the PE standard 
peak, etc. 
 
2.10 Fatty Acyl-CoA Analysis 
 After 180 min of infusion, animals continuing to be infused were anaesthetized with 5% 
isoflurane and the median lobe of the liver was freeze-clamped, collected, immediately placed in liquid 
nitrogen and stored at -80°C for acyl-CoA analysis.  Liver samples were pulverized under liquid nitrogen 
and acyl-CoAs extracted as performed previously [32].  Briefly, 10 mg of liver was homogenized for 150s 
in 500 L of 150 mM aqueous ammonium bicarbonate, then mixed with 500 L of 3:1:1 
acetonitrile:isopropanol:methanol and sonicated for 3 min at 4°C.  The homogenate was centrifuged at 16 
000 g for 10 min and the supernatant collected.  The remaining pellet was extracted again and the 
supernatants were combined into one vial and dried under nitrogen.  The solid residue was then re-
suspended in 500 L of 15 mM sodium hydroxide in 1:1 water:methanol, centrifuged at 14 000 g for 5 
min and the supernatant collected for LC-MS/MS analysis. 
Fatty acyl-CoA liver extracts were detected using a Waters ACQUITY UPLCI-Class system 
(Waters Inc.) and a5500 QTRAP mass spectrometer (Applied Biosystems, Fosters City, CA) equipped 
with a Waters ACQUITY UPLC BEH C8 column (2.1 x 100 mm, 1.7μm).  The initial HPLC conditions 












and 5% B (acetonitrile with 15 mM ammonium hydroxide). The initial gradient was maintained for 1.5 
minutes, and eluent B was linearly increased to 37.8% over 8.5 min, then to 100% over 1 min and finally 
rinsed for 2 min with 100% B and allowed to equilibrate to the starting conditions for 5 minutes.  The MS 
was operated in positive electrospray ionization mode with a source temperature of 500 °C and the ion 
spray voltage setting of 5500 eV. Data was acquired by multiple reaction monitoring (MRM) mode with 
mass transitions as follows: 1028.4 to 521.4 (m/z) for ALA-CoA, 1052.3 to 545.3 for  EPA-CoA, 1078.3 
to 571.3 for DHA-CoA and 1020.6 to 513.5 for the internal standard 10Z heptadecenoyl Coenzyme A.  
Sample concentrations were calculated by plotting peak area ratios (analyte/internal standard) against 
calibration curves generated from extracted standard mixes. 
 
2.11 Equations 










C-PUFA] x plasma volume vs. time) using nonlinear regression [17] (Graphpad 
Prism Version 4.0, La Jolla, CA, USA).  At any point on the curves, the slope (S) is determined by the 








C20-EPA and the 
ability of the periphery to uptake 
2
H5-PUFA (equation 1) or 
13











C20-PUFA]esterified   (Eq. 2) 
 
Where k1,PUFA is the steady-state synthesis-secretion coefficient for any PUFA, representing a measure for 





EPA]unesterified are the plasma concentrations of the infusate, k-1,PUFA is the disappearance coefficient for any 
















that has been synthesized from the respective infusate, packaged into lipoprotein and secreted into the 
plasma.  
 The maximum first derivative (Smax) of the curves are assumed to be the time point when the 




H5-ALA]unesterified – 0  (Eq. 3) 
Smax = k1,PUFA[
13
C20-EPA]unesterified – 0  (Eq. 4) 
 





secretion.  By correcting the Smax by the substrate tracee:tracer ratio, the rates of actual PUFA synthesis 
are determined, Jsyn,PUFA (nmol/min) [17]. 
 
Jsyn,PUFA = Smax ([ALA]unesterified / [
2
H5-ALA]unesterified) = k1,DHA[ALA]unesterified  (Eq. 5) 
Jsyn,PUFA = Smax ([EPA]unesterified / [
13
C20-EPA]unesterified) = k1,DHA[EPA]unesterified  (Eq. 6) 
 
The diet consumed for this study contained no n-3 PUFA other than ALA and/or DHA, therefore 
it can be assumed that the plasma total n-3 PUFA were constant during the infusion period. Therefore, the 
turnover rate (FPUFA) and half-life (t1/2,PUFA) of total n-3 PUFA in the plasma can be determined by Eq. 7 
and  8, respectively.  
FPUFA = Jsyn,PUFA / (Vplasma*[PUFA]esterified)      (Eq. 7) 
t1/2,PUFA = 0.693 / FPUFA        (Eq. 8) 
 The same equations were used for determination of synthesis-secretion kinetic parameters of n-6 
PUFA from unesterified LNA (
13














2.12 Gene Expression 
 mRNA expression was determined by reverse transcriptase qualitative polymerase chain reaction 
(RT-qPCR). RNA extraction was performed using Trizol reagent (Invitrogen Co., Frederick, MD) and 
RNA was isolated and assessed as described previously [33].  Briefly, RNA was separated from other 
cellular components using chloroform, the RNA was centrifuged to a pellet, washed in ethanol and 
dissolved in deionized water.  RNA was measured for purity using a NanoDrop 2000c spectrophotometer 
(Thermo Scientific, Wilmington, DE) and subsequently reverse transcribed to cDNA with reverse 
transcriptase for higher stability with a MJ mini personal thermal cycler (Biorad Laboratories, 
Mississauga, ON). Aliquots of cDNA were loaded onto a 96-well PCR plate along with forward and 
reverse primers for the genes of interest and Fast SYBR Green master mix fluorescent dye (Applied 
Biosystems, Streetsville, ON) to bind to the double stranded DNA allowing detection of the amplified 
qPCR products. The samples were incubated at 95°C for 10 min, followed by 40 cycles of 95°C and 60°C 
in order to amplify the target sequence using a Biorad CFX Real-Time PCR detection system (Biorad).  
The threshold cycle number (Ct) for target genes FADS1 (F – 5’ CCTCTTGTAAAGCACGAGCC, R – 
5’ CAAGGGGTCACACTGTTCCT), FADS2 (F – 5’ TCAAAACCAACCACCTGTTCTTC, R – 5’ 
ACCAGGCGATGCTTTCCA), ELOVL2 (F – 5’ TGCTTGCCCGTGAGAGCCAC, R – 5’ 
TGCCACAGGAAGGCGACGAC), ELOVL5 (F – 5’ CTCTCGGGTGGCTGTACTTC, R – 5’  
AGAGGCCCCTTTCTTGTTGT), ACSL3 (F – 5’ GGCTACTCTTCACCACAGACA, R – 5’ 
CGATCCATGATTTCCGGCAC) and ACSL6 (F – 5’TGAATGCACAGCTGGGTGTA, R – 5’ 
ATGTGGTTGCAGGGCAGAG) were expressed relative to the Ct of the 18S housekeeping gene 
(Sigma-Aldrich; F – 5’ GATCCATTGGAGGGCAAGTCT, R – 5’ 
AACTGCAGCAACTTTAATATACGCTATT).  The expression of target genes were then determined 
using the 2
-Ct















 Differences between dietary protocols for all dependent measures were assessed by one-way 
ANOVA followed by Tukey’s HSD post-hoc test.  Normality was assessed by the Shapiro-Wilk test for 
normality, and in the case of non-normally distributed groups, the data was log transformed prior to 















3.    Results 
3.1  Fatty Acid Concentrations 
 Plasma unesterified fatty acid concentrations were determined two days prior to infusions and 
plasma unesterified infusate concentrations were determined as an average throughout the 180 min 
infusion period.  Specific activity ([unesterified fatty acid infusate]/[endogenous unesterified fatty acid]) 
is also reported (Figure 2).  No differences (p > 0.05) were determined for plasma unesterified ALA 
across the four dietary conditions (6.7 ± 1.5 to 14.5 ± 2.7 nmol/mL), however the 3-hour average plasma 
unesterified 
2
H5-ALA was higher (p > 0.05) in the 8DHA group (1.0 ± 0.1 nmol/mL) compared to all 
other dietary groups (0.5 ± 0.1 to 0.7 ± 0.1 nmol/mL). Specific activity was not different (p > 0.05) 
between the four dietary conditions.  Plasma unesterified EPA was higher (p < 0.05) in the 4DHA (2.2 ± 
1.2 nmol/mL) and the 8DHA groups (2.1 ± 0.5) compared to the 0DHA (0.33 ± 0.03) and 2DHA groups 
(0.7 ± 0.3) with no differences (p > 0.05) in the concentration of the plasma 
13
C20-EPA infusate.  As a 
result of the high endogenous plasma EPA concentrations in the 4DHA and 8DHA groups, the measured 
specific activities of 0.09 ± 0.02 for both are significantly lower (p < 0.05) than determined following the 
0DHA dietary intervention (0.48 ± 0.12).  
Plasma esterified n-3 PUFA concentrations were used to determine turnover of newly synthesized 
n-3 PUFA for each dietary conditions (Table 1).  Only EPA and DHA total plasma concentrations were 
higher (p < 0.05) after 4 and 8 weeks of dietary DHA compared to the 0DHA condition.  Plasma EPA 
was 1.6 and 1.4-fold higher and plasma DHA was 2.3 and 1.6-fold higher in the 4DHA and 8DHA 
groups, respectively, compared to the 0DHA control group.  Interestingly, 18:4n-3 and 20:3n-3 were 3- 
and 0.9-fold lower (p < 0.05), respectively, in the 2DHA group compared to 0DHA and this was 
maintained in the 8DHA group.  Only 20:4n-3, n-3 tetracosapentaenoic acid (TPAn-3, 24:5n-3) and 
tetracosahexaenoic acid (THA, 24:6n-3) showed no differences (p > 0.05) across all dietary conditions.  
For plasma n-6 PUFA, 18:3n-6, 20:2n-6, 22:4n-6, 22:5n-6, 24:4n-6 and 24:5n-6 were all lower (p < 0.05) 
in the 2DHA group compared to the 0DHA group, and this was maintained in the 4DHA and 8DHA 












3.2  Lipid and Acyl-CoA Species 
 Concentrations of DHA and EPA-containing phospholipid species and one DHA-containing 
triacylglycerol (TAG) were measured in whole blood collected two days before infusions and presented in 
Figure 3. The PC species 16:0/DHA-PC (50 ± 5 and 46 ± 4 nmol/mL) and 18:0/DHA-PC (87 ± 13 and 65 
± 7) were higher (p < 0.05) following the 4DHA and 8DHA dietary protocols, respectively, compared to 
0DHA (26 ± 4 and 38 ± 7, respectively). In addition, 16:0/DHA-phosphatidylethanolamine (PE) was 
higher (p < 0.05) in the 2DHA (9.2 ± 1.5) and 8DHA group (7.2 ± 0.5) compared to 0DHA (3.1 ± 0.4) 
and 18:0/DHA-phosphatidylserine (PS) was higher in the 4DHA group (18 ± 1.3) and higher still (p < 
0.05) in the 8DHA group (34 ± 2.3) compared to both 0DHA (5.1 ± 1.7) and 2DHA groups (9.2 ± 1.0).  
Finally, 16:0/EPA-PC was higher (p < 0.05) in the 8DHA group (10.1 ± 0.8) compared to the 0DHA 
control group (6.6 ± 0.8).  No differences (p > 0.05) between dietary conditions were determined for 
16:1/DHA-PC, 18:1/DHA-PC, 18:0/EPA-PC or 16:0/18:1/DHA-TAG. 
 Liver fatty acyl-CoA concentrations (ng/mg) were also determined and presented for ALA, EPA 
and DHA-CoA (Figure 4).  No differences (p > 0.05) were detected across dietary groups for ALA-CoA 
or EPA-CoA.  DHA-CoA was 67 – 94% higher (p < 0.05) in all dietary DHA groups compared to the 
0DHA group (0.12 ± 0.02 ng/mg). 
 
3.3  PUFA synthesis-secretion coefficients, rates, turnover rates and half-lives 
Synthesis-secretion parameters for EPA, DPAn-3 and DHA were determined from plasma 
unesterified ALA as well as for DPAn-3 and DHA from plasma unesterified EPA for maximum first 
derivative (Smax, nmol/min), synthesis-secretion coefficient (k1,n, nmol/min), daily synthesis-secretion 
rates (nmol/day), turnover (%/day) and halflife (days) (Table 2).  The synthesis-secretion coefficients for 
EPA synthesis from ALA were 4.4, 4.4 and 10.3-fold higher (p < 0.05) after 2 weeks of dietary DHA 
(2DHA group) compared to 0, 4 and 8 weeks of DHA feeding, respectively.  Similarly, the synthesis-
secretion coefficient for DPAn-3 synthesis from ALA was 8.7-fold higher (p < 0.05) in the 2DHA group 












determined for newly synthesized DPAn-3 from the plasma unesterified ALA pool in the 2DHA group 
compared to 0DHA. An 11.5-fold higher (p < 0.05) synthesis-secretion coefficient for DPAn-3 from 
plasma unesterified EPA was also identified in the 2DHA group compared to 8DHA, and a 14.4-fold 
faster turnover and 3.6-fold shorter half-life was determined in the 2DHA versus 0DHA group. Synthesis-
secretion kinetic parameters for DHA from plasma unesterified ALA showed no differences (p > 0.05) for 
any measure.  Strikingly, the daily synthesis-secretion rate for DHA from plasma unesterified EPA was 
11-fold higher (p < 0.05) in the 4DHA group compared to the 0DHA group.  As a summary, daily 
synthesis-secretion rates (nmol/d, means ± SEM) for the sum of EPA, DPAn-3 and DHA were 957 ± 412, 
6939 ± 4044, 1996 ± 636 and 1037 ± 312 from ALA (p = 0.093), and 313 ± 85, 2380 ± 1093, 3393 ± 
1905 and 771 ± 217 from EPA (p = 0.065) for the 0DHA, 2DHA, 4DHA and 8DHA groups, respectively 
(data not shown). 
 A similar trend for PUFA synthesis-secretion kinetics were determined for other n-3 PUFA from 
plasma unesterified ALA (Supplemental Table 3) and EPA (Supplemental Table 4).  For example, the 
synthesis-secretion coefficients for stearidonic acid (SDA, 18:4n-3), 20:3n-3 and THA were 6.5, 5.5 and 
10.4-fold higher (p < 0.05) in the 2DHA group compared to the 8DHA group.  Furthermore, turnover is 
faster and half-lives shorter for ALA in the 2DHA and 4DHA groups compared to 0DHA, for SDA in the 
2DHA group compared to the 0DHA and 8DHA groups, and for 20:3n-3 in the 2DHA group compared to 
the 0DHA group.  In addition, the TPAn-3 synthesis-secretion coefficient from EPA is 1.6-fold higher (p 
< 0.05) in the 4DHA group compared to 8DHA.  Finally, similar effects of 2 weeks DHA feeding on n-6 
PUFA synthesis-secretion kinetic measures from plasma unesterified LNA were determined 
(Supplemental Table 4). 
  
3.4  Gene Expression 
 Expression of mRNA targets were determined in liver samples collected immediately following 
180 min infusions and are reported in Figure 5.  Expression of fatty acid desaturase 2 (FADS2) gene 












group with no other differences shown between dietary conditions.  Similarly, ELOVL2 encoding for the 
elongase-2 enzyme was 74% lower (p < 0.05) in the 4DHA group compared to 8DHA, but did not obtain 
statistical significance compared to the 0DHA group (p = 0.055).  No significant differences (p > 0.05) 













4.    Discussion 
 In the present study, we demonstrate higher synthesis-secretion coefficients after 2 weeks of 
DHA feeding compared to 8 weeks of DHA feeding for the synthesis of DPAn-3 from plasma 
unesterified ALA and EPA, and for the synthesis of EPA from plasma unesterified ALA.  Furthermore, 
synthesis-secretion coefficient for EPA synthesis from ALA is more than 5 times higher in the 2DHA 
group compared to 0DHA (Table 2).  Most strikingly, we demonstrate an 11-fold higher daily synthesis-
secretion rate for DHA from plasma unesterified EPA in the 4DHA group compared to the 0DHA group.  
Similarly, high synthesis-secretion coefficients for 18:4n-3, 20:3n-3 and THA from plasma unesterified 
ALA (Supplemental Table 1), 24:5n-3 from EPA (Supplemental Table 2) and 20:2n-6 from LNA 
(Supplemental Table 3) were determined for the 2DHA and/or 4DHA groups.  In addition, higher daily 
synthesis-secretion rates were determined for 18:4n-3 from ALA in the 2DHA group compared to 8DHA 
(Supplemental Table 1), and for 20:2n-6 and 20:3n-6 from LNA in the 2DHA group compared to 0DHA 
(Supplemental Table 3).  Furthermore, 8 weeks of DHA feeding (8DHA) yielded no significant 
differences compared to no DHA (0DHA) for all kinetic measures except for the half-life of newly 
synthesized DPAn-3 from plasma unesterified EPA that was 4.3-fold lower in the 8DHA group.  Our 
kinetic determinations for the ALA-only diet (0DHA) are in reasonable agreement with a recently 
published article assessing all n-3 and n-6 PUFA on the same diet during the same 8-week feeding period 
[28].  
To the best of our knowledge, this is the first study to demonstrate that a chronic 8-week DHA 
feeding protocol compared to an ALA-only control does not affect synthesis rates or kinetics of any 
downstream n-3 PUFA, including DHA.  In fact, the synthesis-secretion kinetics of DHA from plasma 
unesterified ALA were remarkably consistent across all diets, despite significantly different synthesis-
secretion kinetics of both DPAn-3 and THA.  This may provide evidence to suggest that the peroxisomal 
-oxidation of THA to DHA is a regulatory step in the DHA synthesis pathway in response to DHA 
feeding.  Our results were surprising as previous studies using oral doses of labeled ALA in adult rats 












DHA diet [22] determined lower conversion of the labeled precursor into DHA.  Similarly, humans fed 
6.5 g/d DHA over 90 days lowered the appearance of labeled DHA in plasma [8], and humans consuming 
1.5 g/d EPA + DHA over 60 days lowered the appearance of labeled EPA and DHA but not DHA [5].  
Diets from both rodent and human studies contained sufficient ALA, and although similarities exist 
between these studies and our own, one key difference exists: the appearance of labeled DHA in plasma 
from an oral dose of labeled ALA is determined over many days and cannot account for 
metabolism/oxidation or storage of both the precursor and the product during this period.  Labeled DHA 
measures following an oral dose of ALA may then be more accurately described as an accumulation of 
labeled DHA that is highly influenced by turnover.  Our 3-hour infusion methodology allows for real-
time kinetic measure determinations in plasma from steady-state levels and prior to DHA uptake into 
peripheral tissues, thereby limiting the contributions from metabolism and storage.  This would suggest 
that faster turnover of DHA – and not DHA synthesis – may be responsible for the lower accretion of 
labeled DHA in orally dosed rodents and humans.  Interestingly, we have shown previously that 
synthesis-secretion rates of all n-3 PUFA appear to be primarily determined by turnover, and not 
synthesis when fed an ALA-only diet [28].  Although, we were unable to demonstrate faster turnover of 
newly synthesized DHA in the 8DHA group, future studies infusing labeled DHA may provide a more 
direct measure of DHA turnover in response to changes in dietary n-3 PUFA intake.  
The finding of a generally higher throughput of both plasma unesterified ALA and EPA in the 
PUFA biosynthesis pathway following acute DHA feeding (2 and 4 weeks) compared to more chronic 
DHA feeding (8 weeks) was unexpected.  This finding could not be explained by a concomitantly higher 
mRNA expression of the genes involved for the encoding of the biosynthesis pathway enzymes – FADS1 
(5-desaturase), FADS2 (6-desaturase), ELOVL2 (elongase-2) or ELOVL 5 (elongase-5) (Figure 5).  In 
fact, ELOVL2 and FADS 2 expression were lower in the 4DHA group compared to the 8DHA group.  
However, this does not exclude the possibility of higher enzyme activity, higher protein content or both.  












despite lower mRNA expression of FADS1 and FADS2 in nutritional models [35, 36].  The higher 
synthesis-secretion coefficient after 2 weeks of DHA feeding for the synthesis of 18:4n-3 from plasma 
ALA and DPAn-3 from EPA identified in our study is indicative of a higher enzyme activity of 6-
desaturase and elongase-2 and/or elongase-5.  Interestingly, gene expression for elongase-2 (ELOVL2) 
and 6-desaturase (FADS2) are significantly lower after 4 weeks of DHA feeding compared to 8 weeks 
of feeding.  This suggests a compensatory reduction in mRNA expression following the higher enzyme 
activity suggested via the synthesis-secretion coefficients after 2 weeks of DHA feeding.  Conversely, 
higher mRNA expression following 8 weeks of DHA feeding may be a compensatory response for lower 
enzyme activity.  We must also consider the possibility that synthesis-secretion kinetics and/or mRNA 
expression could be highest following even shorter DHA feeding periods (i.e. one week), and future 
studies should attempt to answer this question.  The disagreement between mRNA expression and 
synthesis-secretion rates is interesting in the context of human populations.  A meta-analysis determined a 
role for both dietary fatty acids and single nucleotide polymorphisms (SNPs) in the FADS gene cluster on 
blood DHA and EPA levels [37].  However, other studies have shown no effect of FADS SNPs on blood 
DHA levels [38, 39].  Variations in the relationship between diet, gene expression and enzyme activity 
may help to understand some of these conflicting findings as they relate to SNPs and blood PUFA levels.  
The metabolic purpose for the increased PUFA biosynthetic throughput is not clear, however, the 
introduction of DHA in the diet may signal an upregulation of the pathway as a means to reach steady-
state blood or tissue DHA levels more rapidly.  Interestingly, very-high ALA feeding (up to 64% in total 
fatty acids) has been shown to achieve similar DHA levels in numerous tissues [40, 41] as compared to 
the present study in plasma, and may further indicate the ability to increase throughput of the pathway in 
response to dietary n-3 changes. However, our 3-hour steady-state infusion model may not solely 









C20-DHA) in the 












complex lipids/lipoproteins and export back into the plasma.  Although the potential role of each of these 
steps cannot be ignored, we have demonstrated that gene expression for ACSL3 and ACSL6 encoding for 
DHA-specific CoA synthetases and the incorporation of DHA into phospholipids and triacylglycerols [42, 
43] are not different across all dietary groups (Figure 5).  In addition, no differences in the levels of liver 
DHA-CoA between the 2DHA, 4DHA or 8DHA were shown which further supports that differences in 
DHA-CoA synthesis was not responsible for the higher synthesis-secretion kinetics determined between 
the 2DHA or 4DHA and 8DHA group, and in turn suggests that changes in the incorporation of DHA into 
complex lipids does not explain the increase in DHA synthesis-secretion from plasma unesterified EPA 
determined after 4 weeks of DHA feeding.  However, the general upregulation of our kinetic model 
makes it difficult to exclude the role that additional alternate pathways may play.  Future studies assessing 
these dietary strategies in knockout or enzyme inhibitor models may help to more precisely elucidate the 
mechanisms involved.  Furthermore, 5-minute tracer infusions can be designed so that newly synthesized 
downstream tracer products can be isolated in the liver prior to export into the plasma [11, 22, 44], 
thereby eliminating or reducing the potential contribution from lipoprotein repackaging and export into 
circulation.  Regardless of the mechanism, we demonstrate a clear upregulation for the mobilization of the 
n-3 PUFA into the plasma pool following an acute 2-week DHA feeding period that appears to involve an 
increase in the synthesis of n-3 PUFA downstream to both ALA and EPA.  
Rodent models of pregnancy have also been shown to increase synthesis and accretion of DHA 
[45] and protein levels of 6-desaturase late in pregnancy [33].  This increase in synthesis is associated 
with increases in specific DHA-containing lipid species in both plasma and liver, most significantly 
16:0/DHA-PC [33].  Furthermore, n-3 blood biomarkers may be able to detect adherence and/or non-
adherence to n-3 dietary advice [46], suggesting that specific EPA or DHA-containing complex acyl-lipid 
species may respond differently to acute or chronic DHA feeding.  It is possible that in a similar manner 
specific lipid species are more responsive to increases in newly synthesized DHA versus exogenously 
derived DHA.  For this reason, we identified the major DHA and EPA-containing lipid species in whole 












the three DHA fed groups, differences may be present when comparing 8 weeks of DHA feeding to even 
more acute DHA intake periods of shorter than two weeks.  Of the nine additional DHA and EPA-
containing lipid species reported, only 18:0/22:6-PS was higher after 8 weeks of feeding compared to 
after 2 and 4 weeks feeding.  This finding identifies 18:0/DHA-PS as a potential blood biomarker for 
chronic dietary DHA intake and may prove to be an important tool for assessing dietary adherence to n-3 
advice, and studies designed more towards answering such questions need to be developed.  
The diets used in our study contained ALA and/or DHA as the only n-3 fatty acids present in the 
diet.  Mechanistically, this allows us to identify the introduction of DHA into the diet acutely as the 
primary influence on the higher n-3 synthesis-secretion kinetics compared to chronic DHA.  However, 
unless taken as a supplement DHA is rarely if ever consumed independently from EPA as both are found 
in high amounts in seafood, fish and fish oil supplements [4], with EPA normally present in higher 
amounts and often as high as twice that of DHA.  The inclusion of EPA in the diet is expected to 
significantly impact the synthesis-secretion rates of DH  [16], as plasma unesterified EPA should 
increase with increased dietary EPA [47].  In our current study, DHA feeding did not increase plasma 
unesterified EPA levels until four weeks of feeding, and this increase is the primary reason for the higher 
DHA synthesis-secretion rates.  Therefore, we hypothesize that acute fish oil feeding providing high 
dietary EPA along with DHA would push this higher rate of DHA synthesis-secretion to occur earlier in 
the feeding period and with greater magnitude.  In order to fully realize the effects of acute DHA feeding 
on synthesis-secretion rates, future studies should be aimed at investigating the effects of acute DHA + 
EPA or fish oil feeding on the synthesis-secretion kinetics of n-3 PUFA from plasma unesterified EPA 
and ALA.   
  In summary, we determined that an acute 2-week DHA feeding period results in higher n-3 
PUFA synthesis-secretion kinetics from plasma unesterified ALA and EPA precursors compared to 
chronic DHA intake, and daily synthesis-secretion rates of DHA from EPA were higher after 4 weeks of 
DHA feeding compared to an ALA-only control.  This upregulation of n-3 synthesis-secretion kinetics 












Furthermore, 8 weeks of DHA feeding did not result in any differences in DHA synthesis-secretion 
kinetics or daily synthesis-secretion rates compared to an ALA-only control, suggesting that turnover of 
DHA may be higher with DHA feeding.  The higher synthesis-secretion kinetics with acute DHA feeding 
was an unexpected yet exciting finding, and suggests that novel dietary strategies such as a repeated acute 
DHA feeding protocol may serve to attain similar tissue and blood DHA levels as chronic DHA intake 
while minimizing dietary requirements.   
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Table 1 – Plasma polyunsaturated fatty acid concentrations following 8 weeks of dietary 
intervention 
  Total N-3 Fatty Acids (nmol/mL) 
Fatty Acid 0DHA 2DHA 4DHA 8DHA 
ALA 62.4 ± 11.7
a 25.5 ± 4.3b 42 ± 4.8ab 32 ± 3.4b 
SDA 1.08 ± 0.16
a 0.27 ± 0.03c 0.61 ± 0.09ab 0.62 ± 0.2bc 
20:3n-3 2.62 ± 0.41
a 1.4 ± 0.18b 1.85 ± 0.31ab 1.4 ± 0.2b 
20:4n-3 1.70 ± 0.27 0.98 ± 0.13 1.55 ± 0.22 1.30 ± 0.21 
EPA 24 ± 2.7
a 28.6 ± 5.3ab 62.8 ± 14.8b 56.7 ± 13.5b 
DPAn-3 28.3 ± 2.8
ab 18.8 ± 1.5a 37.9 ± 6.1b 23.4 ± 2.2a 
DHA 164 ± 22
a 309 ± 29ab 534 ± 67c 425 ± 47bc 
TPAn-3 0.47 ± 0.04 0.33 ± 0.04 0.53 ± 0.1 0.36 ± 0.04 
THA 3.15 ± 0.33 2.19 ± 0.25 3.37 ± 0.61 2.86 ± 0.40 
  Total N-6 Fatty Acids (nmol/mL) 
Fatty Acid  0DHA 2DHA 4DHA 8DHA 
LNA 1498 ± 88 1228 ± 69 1427 ± 59 1371 ± 64 
GLA 22.2 ± 2.2
a
 11.4 ± 1.1
b
 17.3 ± 1.9
ab
 22 ± 6.8
a
 
20:2n-6 24 ± 3
a
 12.3 ± 1.3
b
 16.5 ± 3.2
ab
 11.8 ± 1.9
b
 
DGLA 36.2 ± 4.8 25.3 ± 3.3 41.6 ± 4.9 45.4 ± 8 
ARA 1473 ± 112 1541 ± 100 1608 ± 86 1444 ± 87 
22:4n-6 53.6 ± 4.7
a
 30.7 ± 2.8
b
 35.7 ± 3.3
b
 17.5 ± 1.8
c
 
DPAn-6 57.8 ± 7
a
 19.2 ± 1.7
b
 14.7 ± 1.3
b
 7.57 ± 0.68
b
 
24:4n-6 0.67 ± 0.03
a
 0.47 ± 0.04
b
 0.44 ± 0.04
bc
 0.32 ± 0.02
c
 
24:5n-6 1.67 ± 0.21
a 0.74 ± 0.11b 0.68 ± 0.11b 0.4 ± 0.05b 
Different superscript letters represent statistically different values between diets as determined by Tukey’s 
post hoc test following a significant one-way ANOVA, p < 0.05.  Values are expressed as means ± SEM, n = 
7 – 8. ALA, -linolenic acid; ARA, arachidonic acid; DGLA, di-homo--linolenic acid; DHA, 
docosahexaenoic acid; DPAn-3, n-3 docosapentaenoic acid; DPAn-6, n-6 docosapentaenoic acid; EPA, 
eicosapentaenoic acid; GLA, -linolenic acid; LNA, linoleic acid; SDA, stearidonic acid; THA, 
tetracosahexaenoic acid; TPAn-3, n-3 tetracosapentaenoic acid; 0DHA, no DHA feeding; 2DHA, 2weeks of 












Table 2 - Kinetic parameters for whole-body synthesis-secretion of EPA, DPAn-3 and DHA from plasma 
unesterified ALA and EPA 











(%/day) Half-life (d) 
ALA 
EPA 
0DHA 0.031 ± 0.013
ab
 0.044 ± 0.016
a
 336 ± 81 2.09 ± 0.55 0.56 ± 0.15 
2DHA 0.115 ± 0.05
a
 0.238 ± 0.104
b
 4679 ± 3635 38.4 ± 34.3 0.27 ± 0.07 
4DHA 0.02 ± 0.006
b
 0.044 ± 0.013
a
 854 ± 330 1.57 ± 0.37 1.17 ± 0.66 
8DHA 0.021 ± 0.002
ab
 0.021 ± 0.001
a
 441 ± 98 2.68 ± 1.46 0.77 ± 0.2 
ANOVA  0.011* 0.005* 0.208 0.045* 0.045* 
DPAn-3 
0DHA 0.029 ± 0.013 0.040 ± 0.015
ab
 464 ± 254 2.09 ± 1.00
a
 1.46 ± 0.6
a
 
2DHA 0.098 ± 0.034 0.194 ± 0.06
a
 2117 ± 775 16.0 ± 6.6
b
 0.38 ± 0.24
b
 
4DHA 0.033 ± 0.015 0.081 ± 0.044
ab
 1011 ± 357 2.88 ± 0.87
ab
 0.4 ± 0.09
ab
 
8DHA 0.018 ± 0.005 0.020 ± 0.008
b
 459 ± 202 3.74 ± 1.47
ab
 0.55 ± 0.15
ab
 
ANOVA  0.064 0.019* 0.139 0.045* 0.045* 
DHA 
0DHA 0.008 ± 0.005 0.01 ± 0.005 157 ± 120 0.12 ± 0.08 48.2 ± 17.1 
2DHA 0.009 ± 0.003 0.02 ± 0.009 143 ± 57 0.06 ± 0.03 41.3 ± 19 
4DHA 0.004 ± 0.001 0.01 ± 0.004 132 ± 39 0.03 ± 0.01 86.2 ± 61.4 
8DHA 0.005 ± 0.001 0.006 ± 0.002 136 ± 56 0.32 ± 0.26 36.2 ± 11.5 






0DHA 0.064 ± 0.027
ab
 0.501 ± 0.149
ab
 243 ± 66 1.12 ± 0.29
a
 1.84 ± 0.87
a
 
2DHA 0.289 ± 0.13
a
 2.041 ± 0.888
a
 2039 ± 994 17.3 ± 10.1
b
 0.40 ± 0.20
b
 
4DHA 0.055 ± 0.022
ab
 0.6 ± 0.196
ab
 2550 ± 1627 5.95 ± 2.97
ab
 0.45 ± 0.15
ab
 
8DHA 0.024 ± 0.003
b
 0.163 ± 0.025
b
 501 ± 159 3.03 ± 0.69
ab
 0.35 ± 0.07
b
 
ANOVA  0.023 0.030 0.113 0.047 0.047 
DHA 
0DHA 0.015 ± 0.005 0.132 ± 0.036 70 ± 22
a
 0.06 ± 0.02 63.3 ± 34.5 
2DHA 0.081 ± 0.046 0.569 ± 0.31 341 ± 199
ab
 0.12 ± 0.06 17.7 ± 5.6 
4DHA 0.021 ± 0.011 0.305 ± 0.17 843 ± 409
b
 0.16 ± 0.08 19.4 ± 5.5 
8DHA 0.015 ± 0.006 0.102 ± 0.036 270 ± 76
ab
 0.11 ± 0.03 14.2 ± 5.1 
ANOVA  0.299 0.411 0.045 0.662 0.622 
Different superscript letters represent statistically different kinetic values between diets and within a kinetic measure for each 
individual n-3 PUFA as determined by Tukey’s post hoc test following a significant one-way ANOVA, p < 0.05.  One-way 
ANOVA p values are represented in italics with a * representing a significance level of p < 0.05. Values are expressed as 
means ± SEM, n = 7 – 8.  ALA – -linolenic acid; DHA, docosahexaenoic acid; DPAn-3 – n-3 docosapentaenoic acid; EPA, 
eicosapentaenoic acid; 0DHA, no DHA feeding; 2DHA, 2weeks of DHA feeding; 4DHA, 4 weeks of DHA feeding; 8DHA, 8 














Figure 1 – Study feeding design and timeline implemented for 8 weeks post-weaning.  ALA, -linolenic acid; 
DHA, docosahexaenoic acid; 0DHA, no DHA feeding; 2DHA, 2weeks of DHA feeding; 4DHA, 4 weeks of DHA 















Figure 2 – Plasma unesterified fatty acid, average labeled unesterified fatty acid infusate and specific activity during 




C20-EPA after an 8-week dietary intervention.  
Different superscript letters represent statistically different values between diets as determined by Tukey’s post hoc 
test following a significant one-way ANOVA, p < 0.05.  Values are expressed as means ± SEM, n = 7 – 8. DHA, 
docosahexaenoic acid; ALA, -linolenic acid; EPA, eicosapentaenoic acid; 0DHA, no DHA feeding; 2DHA, 















Figure 3 – Concentrations of most abundant EPA and DHA-containing lipid species in whole blood following 8 
weeks of dietary intervention.  Different superscript letters represent statistically different concentrations between 
diets and within lipid species as determined by Tukey’s post hoc test following a significant one-way ANOVA, p < 
0.05.  Values are expressed as means ± SEM, n = 7 – 8.  DHA, docosahexaenoic acid; PC, phosphatidylcholine; PE, 
phosphatidylethanolamine; PS, phosphatidylserine; TAG, triacylglycerol; 0DHA, no DHA feeding; 2DHA, 2weeks 















Figure 4 – ALA-CoA, EPA-CoA and DHA-CoA liver concentrations following 8 weeks of 
dietary intervention.  Different superscript letters represent statistically different 
concentrations between diets and acyl-CoA species as determined by Tukey’s post hoc test 
following a significant one-way ANOVA, p < 0.05.  Values are expressed as means ± SEM, 
n = 7 – 8.  ALA, -linolenic acid; CoA, coenzyme A; DHA, docosahexaenoic acid; EPA, 
eicosapentaenoic acid; 0DHA, no DHA feeding; 2DHA, 2weeks of DHA feeding; 4DHA, 4 
















Figure 5 – Liver mRNA expression following 8 weeks of dietary intervention.  
Different superscript letters represent statistically different concentrations between 
diets and acyl-CoA species as determined by Tukey’s post hoc test following a 
significant one-way ANOVA, p < 0.05.  Values are expressed relative to the 0DHA 
group as means ± SEM, n = 7 – 8.  ACSL, long-chain fatty acyl-CoA synthetase; 
CoA, coenzyme A; DHA, docosahexaenoic acid; ELOVL, elongation of very long-
chain; FADS, fatty acid desaturase; 0DHA, no DHA feeding; 2DHA, 2weeks of DHA 














1. Isotopic fatty acid kinetic modelling is determined after dietary DHA feeding 
2. Synthesis-secretion coefficients for EPA and DPAn-3are higher after 2 weeks DHA 
3. Daily DHA synthesis-secretion rate is higher after 4 weeks DHA 
4. DHA kinetics are not different after 8 weeks DHA compared to ALA 
5. ELOVL2 and FADS2 expression are lower after 4 weeks compared to 8 weeks DHA  
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